RecruitingNot ApplicableNCT06696326

A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer

Sponsor

The First Affiliated Hospital of Xiamen University

Enrollment

100 participants

Start Date

Oct 1, 2024

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer Positron-Emission Tomography(PET)Trophoblast Cell Surface Antigen 2

Summary

The main objective of this research is to develop and evaluate new PET imaging agents with high sensitivity and specificity for prostate cancer and other aggressive tumors. Specifically, the research focuses on improving upon existing prostate cancer imaging methods, such as PSA tests and PSMA PET/CT, which have limitations in sensitivity, specificity, and the ability to provide comprehensive tumor information，and aims to create a novel PET probe targeting Trop2, an antigen highly expressed in multiple cancer types, to enable in vivo, whole-tumor assessment. This would support early diagnosis, more precise staging, and effective monitoring of cancer therapy.

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating a new type of imaging scan (called 68Ga-MY6349 PET/CT) that may help detect prostate cancer more accurately, including cases where the cancer has come back after surgery or radiation treatment. **You may be eligible if...** - You have been newly diagnosed with prostate cancer, OR - You have had a rise in your PSA blood test after prostate surgery or radiation (called biochemical recurrence) - Doctors estimate you have at least 3 months to live - You are willing and able to follow all study procedures **You may NOT be eligible if...** - You are unable to tolerate intravenous injections (for example, due to needle or blood phobia) - Your doctor determines you are otherwise unsuitable for the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTstandard-of-care imaging 68Ga-MY6349 and 68Ga-PSMA-11

Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals 68Ga-MY6349 and 68Ga-PSMA-11, and undergoes PET/CT imaging within the specified time.

Locations(1)

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06696326

Related Trials

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

NCT0733644618 locations

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT0700515433 locations

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

NCT046926751 location

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

NCT068073593 locations

DESTINY-PANTUMOUR04

NCT0712400017 locations